Certara, Inc. (NASDAQ:CERT) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 260,454 shares of the company’s stock after selling 16,998 shares during the quarter. Rhumbline Advisers owned about 0.16% of Certara worth $2,578,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CERT. Vontobel Holding Ltd. acquired a new stake in Certara during the fourth quarter worth $1,295,000. Principal Financial Group Inc. increased its stake in Certara by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock worth $5,660,000 after acquiring an additional 15,739 shares during the last quarter. CIBC Asset Management Inc purchased a new position in shares of Certara during the fourth quarter worth $132,000. Venturi Wealth Management LLC boosted its position in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the period. Finally, Private Advisor Group LLC purchased a new position in shares of Certara during the fourth quarter worth $251,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Down 1.5%

NASDAQ:CERT opened at $11.01 on Monday. The firm has a market cap of $1.79 billion, a PE ratio of -55.05, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44. The stock has a fifty day moving average price of $12.22 and a 200 day moving average price of $11.88. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $16.93. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. Sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on CERT shares. JMP Securities restated a “market perform” rating on shares of Certara in a research report on Tuesday, May 6th. Robert W. Baird raised their price target on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target for the company. Finally, Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Certara presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.